Episode Details

Back to Episodes

281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

Published 2 years, 11 months ago
Description

Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.

For more on what we cover, here's where you can read Frank's work; here's more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here's where you can subscribe to our biotech newsletter, The Readout.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us